May 2016

New Product - Infanrix

Infanrix (diphtheria toxoid, tetanus toxoid and three purified antigens of Bordetella pertussis [pertussis toxoid (PT), filamentous haemagglutinin (FHA) and pertactin (PRN)]. The diphtheria and tetanus toxins are obtained from cultures of Corynebacterium diphtheriae and Clostridium tetani and are then detoxified and purified. The acellular pertussis vaccine components (PT, FHA and PRN) are extracted from phase I Bordetella pertussis, and are then purified and stabilised. Infanrix is indicated for active primary immunisation against diphtheria, tetanus and pertussis when commenced between 2 months and 12 months of age. Infanrix (DTPa) is also indicated as fourth and fifth dose for children from 15 months of age up to and including 6 years of age who have been immunised previously with three or four doses of diphtheria, tetanus and pertussis (whole cell or acellular) vaccine. As with other vaccines, the administration of Infanrix should be postponed in subjects suffering from acute severe febrile illness. Infanrix is contraindicated if the child has experienced an encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis containing vaccine. In these circumstances the vaccination course should be continued with diphtheria and tetanus vaccine. Infanrix is available as a 0.5 mL glass prefilled syringe containing not less than 30 IU of diphtheria toxoid, 40 IU of tetanus toxoid, 25 microgram of PT, 25 microgram of FHA and 8 microgram of PRN in packs of 1’s and 10’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629